Monitoring of von Willebrand Factor Inhibitors in Patients with Type 3 von Willebrand Disease Using a Quantitative Assay
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Monitoring of von Willebrand Factor Inhibitors in Patients with Type 3 von Willebrand Disease Using a Quantitative Assay

Filetype[PDF-353.12 KB]


English
Details Supporting Files You May Also Like

Details:

  • Alternative Title:
    Haemophilia
  • Personal Author:
    Miller, Connie H.
  • Description:
    Background:

    Antibodies inhibiting von Willebrand factor (VWF) develop in a subset of patients with Type 3 von Willebrand disease (VWD3) and may be detected by their inhibition of ristocetin cofactor activity (VWF:RCo). Some also inhibit factor VIII activity (VIII:C).

    Aim:

    To describe monitoring of ten VWD3 patients for VWF inhibitors using a quantitative assay.

    Methods:

    VWF inhibitor was measured by comparing VWF:RCo activity of a mix of patient and pooled normal plasma (PNP) with a mix of buffer and PNP, using agglutination of fixed normal platelets in microtiter plates or lyophilized platelets in an aggregometer. VIII:C inhibitor was measured by Bethesda assay. Preanalytical heat treatment of patient plasma was used during treatment episodes.

    Results:

    Four of 10 patients monitored developed VWF inhibitors, 2 detected during bleeding episodes refractory to treatment and 2 on routine screening. Data from the first 5 patients were used to establish an arbitrary unit, VWU, defined as the amount of inhibitor per mL of patient plasma inactivating 25% of the activity of 1 mL of PNP. In 3 of 4 patients, both VWF:RCo and VIIII:C were inhibited at some time points, although VIII:C inhibition sometimes disappeared. In one patient, no VIII:C inhibition was seen. Two patients remained inhibitor positive more than 15 years after inhibitor detection, one became negative following immune tolerance induction, and one was deceased.

    Conclusions:

    VWF inhibitors can be quantitatively monitored in VWD3 patients. Preanalytical heat treatment may be required for their detection post infusion.

  • Subjects:
  • Source:
    Haemophilia. 27(5):823-829
  • Pubmed ID:
    34089550
  • Pubmed Central ID:
    PMC8667261
  • Document Type:
    Journal Article
  • Funding:
    CC999999/ImCDC/Intramural CDC HHSUnited States/
  • Volume:
    27
  • Issue:
    5
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

You May Also Like

Checkout today's featured content at stacks.cdc.gov